Vaccine composition and preparation method thereof

A vaccine composition and buffer technology, applied in the field of vaccine compositions, can solve problems such as virus-like particles of vaccine products that are not disclosed, and achieve the effects of removing viruses and improving efficacy

Active Publication Date: 2015-05-20
PU LIKE BIO ENG +1
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent CN103173470A discloses the preparation of a virus-like particle, but does not disclose that its vaccine product contains virus-like particles that can maintain stable existence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine composition and preparation method thereof
  • Vaccine composition and preparation method thereof
  • Vaccine composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Preparation and inspection of embodiment 1PCV2 subunit vaccine

[0034] 1. Preparation of Cap protein stabilization buffer

[0035] In this embodiment, the most preferred formula is used to prepare the buffer solution. The specific steps are as follows. Use water for injection to prepare a disodium hydrogen phosphate solution with a concentration of 50 mM, adjust the pH to 6.8 with phosphoric acid, add sodium chloride to make the final concentration 1100 mM, and use it after the solution is completely prepared. Filter through a 0.22 μm filter membrane, seal and store at room temperature for later use. The detailed formulation is shown in Table 1 below.

[0036] Table 1 Preparation of VLPs stabilization buffer (1000ml)

[0037]

[0038] 2. Vaccine preparation

[0039] Add a weighed amount of GEL adjuvant to a sterilized beaker. According to Examples 1-3 of patent CN103173470A, the PCV2 protein virus-like particle antigen was prepared with a content of 1.3 mg / ml. ...

Embodiment 2

[0050] Example 2 PCV2 subunit vaccine prevents and treats the efficacy of PCV2 infection

[0051] 1. Comparative study on the effect of immunizing piglets with different doses of PCV2 subunit vaccine

[0052] In this example, the effects of five PCV2 candidate vaccines were tested, and the efficiency parameters after exposure to virulent PCV2 strains were further determined. Thirty-five 9-14-day-old piglets that did not eat colostrum were randomly divided into 7 groups of the same size, with 5 pigs in each group. Group 1 was injected with 1ml of PCV2 subunit vaccine V1 (60μg / ml) in neck muscle, group 2 was injected with 1ml of PCV2 subunit vaccine V2 (30μg / ml) in neck muscle, and group 3 was injected with PCV2 subunit vaccine V3 in neck muscle (10μg / ml) 1ml, the 4th group intramuscular injection of PCV2 subunit vaccine V4 (5μg / ml) 1ml, the fifth group intramuscular injection of PCV2 subunit vaccine V5 (2μg / ml) 1ml, the sixth group no immunization , as the challenge control...

Embodiment 3

[0119] Embodiment 3 PCV2 subunit vaccine stability research

[0120] Dr. Yin Shuanghui of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences reported "Preparation and Immunogenicity of Porcine Circovirus Type 2 Capsid Protein Virus-Like Particles", which used the Escherichia coli expression system to prepare PCV2Cap VLPs as antigen inoculation In pigs, the antibody can turn positive 7 days after immunization, and the antibody still shows an upward trend until 28 days after immunization. According to its technical scheme and route, we constructed His-SUMO-Cap, and obtained natural Cap protein through affinity chromatography purification. After the antigen was emulsified with complete Freund's adjuvant, the stability of PCV2 subunit vaccine was studied as a comparison vaccine Va.

[0121] Patent application CN103122352A discloses a porcine circovirus type 2 recombinant baculovirus and a preparation method thereof. The method uses a baculovirus ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a vaccine composition, which comprises an immunizing dose of PCV2Cap protein virus-like particle antigen and a stable buffer solution. In the vaccine composition, the PCV2Cap protein can stably exist in the form of virus-like particles, and after preservation of different time, the effect is obviously better than a contrast vaccine.

Description

technical field [0001] The present invention relates to a vaccine composition, in particular to an anti-circovirus vaccine composition. Background technique [0002] Porcine circovirus (PCV) is the smallest animal virus ever discovered. PCV is known to have two serotypes, PCV1 and PCV2. PCV1 is a non-pathogenic virus. PCV2 is a pathogenic virus that is the main cause of multisystemic wasting syndrome (PMWS) in weaned piglets. The clinical features of PMWS include weight loss, pale skin, dyspnea, diarrhea, and jaundice. Pathological changes can be seen systemic lymph node enlargement, especially inguinal lymph node enlargement up to 5 to 10 times; the lungs mainly show diffuse and interstitial pneumonia changes, the texture is as hard as rubber, and the surface generally has a taupe mottled appearance; the kidney There are many changes, white necrotic lesions of different sizes can be seen scattered in the cortex and medulla, which appear waxy due to edema; the spleen is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/12A61K39/39A61P31/20
Inventor 张许科袁于人孙进忠莫小兵田克恭
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap